Tevogen bio expands on microsoft partnership to integrate machine learning and ai into preclinical processes, accelerating drug development and reducing costs

Warren, n.j., oct. 31, 2024 (globe newswire) -- tevogen bio (“tevogen” or “tevogen bio holdings inc.”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t cell therapeutics to treat infectious disease and cancers, shares details of its partnership with microsoft (nasdaq: msft) for startups.
MSFT Ratings Summary
MSFT Quant Ranking